Michael Triplett is President of Carmen Partners, a life science ventures and innovation advisory firm. Michael is Co-Founder, President, and CEO of Armatus Bio LLC, a gene and cell therapy company based in Columbus. He is also Co-Founder, President, and initial CEO of Clarametyx Biosciences, Inc. a startup infectious disease company spun out of Nationwide Children’s Hopsital pursuing novel therapeutics and vaccines for the treament and prevention of chronic and recurrent bacterial infections. Previously, Michael Co-Founded and served as President and CEO of Myonexus Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-girdle muscular dystrophies that Sarepta Therapeutics (SRPT) acquired for north of $225 million in April of 2019. In addition to his biotech entrepreneurial efforts Michael is currently leading an InnovateOhio Gene and Cell Therapy Workgroup for Ohio Lieutenant Governor, Jon Husted, with the mission to propose gene and cell therapy economic development strategies for the State of Ohio.